These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 21984976)

  • 61. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
    Kanamori Y; Kigawa J; Itamochi H; Shimada M; Takahashi M; Kamazawa S; Sato S; Akeshima R; Terakawa N
    Clin Cancer Res; 2001 Apr; 7(4):892-5. PubMed ID: 11309338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Oda K
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
    Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
    Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
    Feigin ME; Akshinthala SD; Araki K; Rosenberg AZ; Muthuswamy LB; Martin B; Lehmann BD; Berman HK; Pietenpol JA; Cardiff RD; Muthuswamy SK
    Cancer Res; 2014 Jun; 74(11):3180-94. PubMed ID: 24662921
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
    Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
    [TBL] [Abstract][Full Text] [Related]  

  • 70. miR‑494‑3p promotes the progression of endometrial cancer by regulating the PTEN/PI3K/AKT pathway.
    Zhu L; Wang X; Wang T; Zhu W; Zhou X
    Mol Med Rep; 2019 Jan; 19(1):581-588. PubMed ID: 30431102
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
    Catasus L; D'Angelo E; Pons C; Espinosa I; Prat J
    Mod Pathol; 2010 May; 23(5):694-702. PubMed ID: 20173732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
    Ekstrand AI; Jönsson M; Lindblom A; Borg A; Nilbert M
    Fam Cancer; 2010 Jun; 9(2):125-9. PubMed ID: 19731079
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.
    Joshi A; Miller C; Baker SJ; Ellenson LH
    Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway.
    Zhang J; Yang Y; Zhang Z; He Y; Liu Z; Yu Y; Wu S; Cai B; Feng Y
    Cancer Lett; 2013 Oct; 339(2):279-87. PubMed ID: 23142288
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
    Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
    Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
    Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
    Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
    Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.